JP2015146811A - 同位体修飾化合物およびフードサプリメントとしてのそれらの使用 - Google Patents
同位体修飾化合物およびフードサプリメントとしてのそれらの使用 Download PDFInfo
- Publication number
- JP2015146811A JP2015146811A JP2015045737A JP2015045737A JP2015146811A JP 2015146811 A JP2015146811 A JP 2015146811A JP 2015045737 A JP2015045737 A JP 2015045737A JP 2015045737 A JP2015045737 A JP 2015045737A JP 2015146811 A JP2015146811 A JP 2015146811A
- Authority
- JP
- Japan
- Prior art keywords
- atom
- composition according
- essential
- nutrient
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 27
- 235000015872 dietary supplement Nutrition 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 235000020774 essential nutrients Nutrition 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 11
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 230000003647 oxidation Effects 0.000 claims description 16
- 238000007254 oxidation reaction Methods 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 230000006315 carbonylation Effects 0.000 claims description 3
- 238000005810 carbonylation reaction Methods 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 235000006286 nutrient intake Nutrition 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims 1
- 229940033080 omega-6 fatty acid Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 10
- 239000000470 constituent Substances 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 230000005855 radiation Effects 0.000 abstract description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract description 2
- 230000009931 harmful effect Effects 0.000 abstract description 2
- 230000000050 nutritive effect Effects 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 description 17
- 239000000306 component Substances 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 11
- 235000020776 essential amino acid Nutrition 0.000 description 10
- 239000003797 essential amino acid Substances 0.000 description 10
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 229910052805 deuterium Inorganic materials 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000007845 reactive nitrogen species Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- -1 oxygen free radical Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 241000244206 Nematoda Species 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 230000005445 isotope effect Effects 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 238000010504 bond cleavage reaction Methods 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- VZSTVUJXUYNIOQ-TXZHAAMZSA-N (2S)-2-amino-4-cyano(113C)butanoic acid Chemical compound N[C@H]([13C](=O)O)CCC#N VZSTVUJXUYNIOQ-TXZHAAMZSA-N 0.000 description 2
- VZSTVUJXUYNIOQ-BYPYZUCNSA-N (2s)-2-amino-4-cyanobutanoic acid Chemical compound OC(=O)[C@@H](N)CCC#N VZSTVUJXUYNIOQ-BYPYZUCNSA-N 0.000 description 2
- AAWKBLYYEHJYCW-YFKPBYRVSA-N (2s)-2-amino-5-cyanopentanoic acid Chemical compound OC(=O)[C@@H](N)CCCC#N AAWKBLYYEHJYCW-YFKPBYRVSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- MKDXZFVCXWXGBQ-VPENINKCSA-N 8-bromo-2'-deoxyguanosine Chemical compound BrC1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 MKDXZFVCXWXGBQ-VPENINKCSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- SAKUKAQFBMDKGX-UHFFFAOYSA-N butan-1-ol;2-pyridin-2-ylacetic acid;hydrate Chemical compound O.CCCCO.OC(=O)CC1=CC=CC=N1 SAKUKAQFBMDKGX-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LFQSCWFLJHTTHZ-LIDOUZCJSA-N ethanol-d6 Chemical compound [2H]OC([2H])([2H])C([2H])([2H])[2H] LFQSCWFLJHTTHZ-LIDOUZCJSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000006318 protein oxidation Effects 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- ODKSFYDXXFIFQN-PPHVBSBQSA-N (2s)-2-amino-5,5-dideuterio-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=N[13C]([2H])([2H])CC[C@H](N)C(O)=O ODKSFYDXXFIFQN-PPHVBSBQSA-N 0.000 description 1
- ODKSFYDXXFIFQN-XHNVGKFISA-N (2s)-2-amino-5,5-dideuterio-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NC([2H])([2H])CC[C@H](N)C(O)=O ODKSFYDXXFIFQN-XHNVGKFISA-N 0.000 description 1
- VVNYDCGZZSTUBC-LURJTMIESA-N (2s)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(N)=O VVNYDCGZZSTUBC-LURJTMIESA-N 0.000 description 1
- SDCAQJCTUOFAKD-UHNVWZDZSA-N (2s,4r)-2-amino-5-hydroxy-4-methylpentanoic acid Chemical compound OC[C@H](C)C[C@H](N)C(O)=O SDCAQJCTUOFAKD-UHNVWZDZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-ZVDPVMROSA-N (9z,12z)-11,11-dideuteriooctadeca-9,12-dienoic acid Chemical compound CCCCC\C=C/C([2H])([2H])\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-ZVDPVMROSA-N 0.000 description 1
- OGAKXVBQIRPUJO-GFCQZRJLSA-N (9z,12z)-11-bromooctadeca-9,12-dienoic acid Chemical compound CCCCC\C=C/C(Br)\C=C/CCCCCCCC(O)=O OGAKXVBQIRPUJO-GFCQZRJLSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- FARHYDJOXLCMRP-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]pyrazol-3-yl]oxyacetic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(N1CC2=C(CC1)NN=N2)=O)OCC(=O)O FARHYDJOXLCMRP-UHFFFAOYSA-N 0.000 description 1
- DXCXWVLIDGPHEA-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-[(4-ethylpiperazin-1-yl)methyl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCN(CC1)CC DXCXWVLIDGPHEA-UHFFFAOYSA-N 0.000 description 1
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 1
- LDRFQSZFVGJGGP-GSVOUGTGSA-N 3-hydroxy-L-valine Chemical compound CC(C)(O)[C@H](N)C(O)=O LDRFQSZFVGJGGP-GSVOUGTGSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- RYIDCNTZKZPKAS-UHFFFAOYSA-N C1=CC=NC=C1.O.O.Cl.Cl.Cl.Cl Chemical compound C1=CC=NC=C1.O.O.Cl.Cl.Cl.Cl RYIDCNTZKZPKAS-UHFFFAOYSA-N 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 150000001975 deuterium Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 231100000613 environmental toxicology Toxicity 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229940124280 l-arginine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000006902 nitrogenation reaction Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001196 time-of-flight mass spectrum Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/30—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Marine Sciences & Fisheries (AREA)
- Birds (AREA)
- Insects & Arthropods (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
Abstract
Description
本発明は、同位体修飾化合物およびフードサプリメントとしてのそれらの使用に関する。
加齢に関する現今の定説は、細胞機構における不可逆的変化ならびに呼吸プロセスの一部として細胞に通常存在するフリーラジカルおよび他の活性酸素種(ROS)または活性窒素種(RNS)の有害な作用に対する代謝プロセスの低下した効率が原因であるとする。ROSおよびRNSは、DNA、タンパク質、脂質および他の細胞構成成分を酸化/ニトロ化する。これらのうち、アルギニン、リシン、スレオニン、トリプトファンおよびプロリンを対応するカルボニル化合物に変換するタンパク質酸化は、特定の閾値数のアミノ酸残基が酸化された後ではプロテアーゼにより修復することができない。
本発明は、摂取された場合、機能的に通常の身体構成物質に等価であるが、分解/有害なプロセス(例えば、ROSおよびRNSまたは放射線により媒介されるプロセス)に対してより耐性を有する、身体構成物質(例えば、タンパク質、核酸、脂質、炭水化物など)の形成を生じるクラスの化合物を合成するために、同位体置換を使用できる、という事実に基づいている。そのため、本発明によれば、栄養組成物は、少なくとも1つの変換可能なH原子が2Hであり、かつ/または少なくとも1つのC原子が13Cである必須栄養素を含む栄養組成物を含む。
図1から4は各々必須栄養素を分解する反応を示す。
本発明は、必須サプリメントが酸化、窒素化などの不可逆的化学変換を受け、老化または疾患の発現を導きうる、という事実に関する。必須食品成分は、生物体(例えば、哺乳動物、霊長類またはヒト)によりデノボ合成することができず、そのため食餌で供給される必要がある。本明細書の目的のために、核酸は必須であるが、条件付きで必須と記載されることがより適切でありうる。条件付きで必須な栄養素は、特定の条件下、食餌で供給される必要がある。
塩化第一銅−ジオキシゲン−ピリジン系に触媒される酸素による直接酸化(Nicolaouら、Synthesis(1986)453〜461;Capdevielleら、Tet.Lett.(1990)31:3305〜3308)
ブロモコハク酸イミドを使用する直接変換(Gottardi、Monatsh.Chem.(1973)104:1690〜1695)
直接ヨードソベンゼン酸化(Moriartyら、Tet.Lett.(1988)29:6913〜6916)
ジ−トシル誘導体およびヨード誘導体を介する2段階変換(DeChristopherら、JACS(1969)91:2384〜2385)。
13C6−グルコース(99%濃縮;Sigma)を大腸菌(Escherichia coli)の培養のための炭素飼料源として使用し、対照は12C6−グルコースを除いて同じであった。C.エレガンス(N2、野生型)を、上記のとおりに調製された大腸菌を播種した標準(ペプトン、塩およびコレステロール)培地で培養した。対応する13C−誘導体が入手不可能であったため、大腸菌を除く唯一の炭素含有成分は、12C−コレステロール(Sigma;C.エレガンスに必須であるホルモン前駆体)であった。したがって、線虫を15〜25℃の温度範囲で、各プール50〜100匹の蠕虫で「重」および「軽」(対照)飼料により培養した。両飼料を与えた動物は正常に成長し、すべての主要な特性は非常に類似していた。
使用した無菌培地の基本構成成分は(Lu & Goetsch Nematologica(1993)39:303〜311)によった。水溶性およびTEA可溶性成分(ビタミンおよび成長因子)、塩、非必須アミノ酸、核酸置換基、他の成長因子およびエネルギー源を記載のとおりに調製した(2倍の0.5L)。これに必須アミノ酸:0.98g L−(D2)−Arg(上記参照);0.283g L−Hys;1.05g L−(D2)−Lys(下記参照);0.184g L−Trp;0.389g L−Met;0.717g L−Thr;1.439g L−Leu;0.861g L−Ile;1.02g L−Valおよび0.623g L−Pheを含む(2倍量として0.5L)混合物を添加した。残りの成分を添加する前に、この混合物を55℃で4時間、透明な溶液が形成されるまで攪拌し、次いで室温まで冷却した。
12C−NGM飼料は5,5−ジ−重水素化−アルギニンおよび6,6−ジ−重水素化−リシン、11,11−ジ−重水素化−リノール酸(18:2)ならびに8−D−デオキシグアノシンを豊富に含んだ。C.エレガンスを、1g/Lの各重水素化化合物の総濃度になるように重水素「補強された」誘導体(上記参照)を添加した、上記のとおりに調製した大腸菌を播種した標準(ペプトン、塩およびコレステロール)培地で培養した。したがって、線虫を「重」および「軽」(対照、非重水素化L−アルギニン、L−リシン、リノール酸(18:2)およびデオキシグアノシンを1g/Lの濃度で重水素化アナログの代わりに使用した)飼料で、15〜25℃の温度範囲で、各プール中50〜100匹の蠕虫で培養した。生存期間のデータを実施例10に記載したとおりにプリズムソフトウェアパッケージを使用して解析した。
Claims (18)
- 少なくとも1つの交換可能なH原子が2Hであり、かつ/または少なくとも1つのC原子が13Cである必須栄養素を含む栄養組成物。
- 必須栄養素が、天然の核酸、脂肪酸もしくはアミノ酸であるか、または前記物質を含む請求項1に記載の組成物。
- 最も酸化されやすい位置でC原子に結合された1つのH原子または各H原子が2Hである、請求項2に記載の組成物。
- C原子が13Cである、請求項3に記載の組成物。
- 酸化が酵素的カルボニル化である、請求項3または4に記載の組成物。
- 前記2Hもしくは13C原子、または各2Hもしくは13C原子が、活性酸素種と反応しやすい位置にある、前記請求項のいずれかに記載の組成物。
- 必須栄養素が、Phe、Val、Trp、Pro、Thr、Ile、Met、His、Arg、LysおよびLeuから選択されるアミノ酸であるか、または前記アミノ酸を含む、請求項2から5のいずれかに記載の組成物。
- アミノ酸が、2,6−ジアミノヘキサン−6,6−D2または明細書中に式が挙げられる別の標識アミノ酸である、請求項7に記載の組成物。
- 必須栄養素がペプチドである、前記請求項のいずれかに記載の組成物。
- 栄養素が核酸またはヌクレオチドである、請求項2から6のいずれかに記載の組成物。
- 栄養素がω−3またはω−6脂肪酸である、請求項2から6のいずれかに記載の組成物。
- 植物性物質を含む、前記請求項のいずれかに記載の組成物。
- 微生物物質を含む、前記請求項のいずれかに記載の組成物。
- 前記請求項のいずれかに記載の組成物である培地中、必須栄養素が生物体により生成される生成物中に同化されるような条件下で生物体を培養する工程を含む食品を調製するための方法。
- 栄養素中に、少なくとも1つの交換可能なH原子が2Hであり、かつ/または少なくとも1つのC原子が13Cである必須栄養素を含める工程を含む対象の栄養摂取の方法。
- 必須栄養素が請求項2から9のいずれかに定義されたとおりである、請求項15に記載の方法。
- 対象がヒトである、請求項15または16に記載の方法。
- 対象が商業用動物または家畜である、請求項15または16に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0604647.8 | 2006-03-08 | ||
GBGB0604647.8A GB0604647D0 (en) | 2006-03-08 | 2006-03-08 | Stabilized food supplements and their derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008557833A Division JP5844955B2 (ja) | 2006-03-08 | 2007-03-08 | 同位体修飾化合物およびフードサプリメントとしてのそれらの使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015146811A true JP2015146811A (ja) | 2015-08-20 |
JP6062470B2 JP6062470B2 (ja) | 2017-01-18 |
Family
ID=36241193
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008557833A Active JP5844955B2 (ja) | 2006-03-08 | 2007-03-08 | 同位体修飾化合物およびフードサプリメントとしてのそれらの使用 |
JP2015045737A Active JP6062470B2 (ja) | 2006-03-08 | 2015-03-09 | 同位体修飾化合物およびフードサプリメントとしてのそれらの使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008557833A Active JP5844955B2 (ja) | 2006-03-08 | 2007-03-08 | 同位体修飾化合物およびフードサプリメントとしてのそれらの使用 |
Country Status (9)
Country | Link |
---|---|
US (5) | US8906405B2 (ja) |
EP (2) | EP1991068B8 (ja) |
JP (2) | JP5844955B2 (ja) |
CA (2) | CA2931996A1 (ja) |
DK (1) | DK1991068T3 (ja) |
ES (1) | ES2639395T3 (ja) |
GB (1) | GB0604647D0 (ja) |
HK (1) | HK1260326A1 (ja) |
WO (1) | WO2007102030A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0604647D0 (en) | 2006-03-08 | 2006-04-19 | Shchepinov Mikhail | Stabilized food supplements and their derivatives |
WO2009114809A1 (en) * | 2008-03-14 | 2009-09-17 | Retrotope, Inc. | Therapies for cancer using isotopically substituted lysine |
WO2009114814A2 (en) * | 2008-03-14 | 2009-09-17 | Retrotope, Inc. | Therapeutic substances that modulate genome methylation |
CA2777827C (en) * | 2009-10-30 | 2020-08-18 | Retrotope, Inc. | Alleviating oxidative stress disorders with pufa derivatives |
DK2588144T3 (en) | 2010-07-02 | 2018-07-23 | Ventana Med Syst Inc | Detection of targets using mass markers and mass spectrometry |
EP3689342A1 (en) | 2011-04-26 | 2020-08-05 | Retrotope, Inc. | Oxidative retinal diseases |
KR102110175B1 (ko) | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | Pufa 산화와 관련된 장애 |
AU2012249917B2 (en) | 2011-04-26 | 2017-06-15 | Biojiva Llc | Neurodegenerative disorders and muscle diseases implicating PUFAs |
JP6093756B2 (ja) | 2011-04-26 | 2017-03-08 | レトロトップ、 インコーポレイテッドRetrotope, Inc. | 損なわれたエネルギー処理障害およびミトコンドリア欠損症 |
WO2013176958A1 (en) * | 2012-05-21 | 2013-11-28 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
ES2889874T3 (es) | 2014-03-13 | 2022-01-14 | Retrotope Inc | Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas |
KR102643910B1 (ko) | 2015-11-23 | 2024-03-06 | 레트로토프 인코포레이티드 | 1,4-다이엔 시스템에 대한 부위 특이적인 동위원소 표지법 |
FR3068135A1 (fr) | 2017-06-26 | 2018-12-28 | Ids Group | Marquage et identification isotopiques des animaux et vegetaux |
CA3096035A1 (en) * | 2018-04-04 | 2019-10-10 | Retrotope, Inc. | Isotopically modified composition and therapeutic uses thereof |
KR20220143931A (ko) | 2020-02-21 | 2022-10-25 | 레트로토프 인코포레이티드 | 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정 |
KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3520872A (en) * | 1967-03-24 | 1970-07-21 | Upjohn Co | Process for labelling purine and pyrimidine containing compounds |
JPH07500566A (ja) * | 1989-11-30 | 1995-01-19 | クロダ・インターナショナル・ピーエルシー | ネルボン酸及び長鎖脂肪酸の脱髄疾患の治療のための使用 |
US5244921A (en) | 1990-03-21 | 1993-09-14 | Martek Corporation | Eicosapentaenoic acids and methods for their production |
US5393669A (en) | 1993-02-05 | 1995-02-28 | Martek Biosciences Corp. | Compositions and methods for protein structural determinations |
FR2721518B3 (fr) | 1994-06-28 | 1996-04-12 | Gattefosse Ets Sa | Compositions cosmétiques, pharmaceutiques, diététiques, vétérinaires contenant de l'eau. |
US5578334A (en) * | 1995-04-07 | 1996-11-26 | Brandeis University | Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends |
JPH10291955A (ja) * | 1997-04-22 | 1998-11-04 | Sagami Chem Res Center | 13c標識ドコサヘキサエン酸及びその製造方法 |
US6111066A (en) * | 1997-09-02 | 2000-08-29 | Martek Biosciences Corporation | Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains |
BR9811716A (pt) | 1997-10-08 | 2000-07-18 | Isotechnika Inc | Análogos de ciclosporina deuterados e o seu emprego como agentes de modulação imunológica |
US6270974B1 (en) | 1998-03-13 | 2001-08-07 | Promega Corporation | Exogenous nucleic acid detection |
DE1075286T1 (de) * | 1998-05-06 | 2002-05-23 | Isotechnika,Inc. | 13C-Glukose-Atemtest zur Diagnose von Diabetes-Indikationen und Überwachung der glykämischen Kontrolle |
IT1304406B1 (it) * | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
US6503478B2 (en) * | 1999-01-13 | 2003-01-07 | Lightouch Medical, Inc. | Chemically specific imaging of tissue |
JP2000290291A (ja) | 1999-03-31 | 2000-10-17 | Nippon Sanso Corp | 安定同位体標識オリゴヌクレオチド及びオリゴヌクレオチド検出方法 |
GB9929897D0 (en) * | 1999-12-18 | 2000-02-09 | Slabas Antoni R | Improvements in or relating to conjugated fatty acids and related compounds |
CZ299784B6 (cs) * | 2001-05-30 | 2008-11-26 | Laxdale Limited | Lécivo obsahující EPA a ubichinon pro lécení non-Hodgkinova lymfomu, psychiatrických a neurologických chorob |
JPWO2004029254A1 (ja) * | 2002-09-30 | 2006-01-26 | 味の素株式会社 | 安定同位体標識タンパク質の製造方法 |
JP4836786B2 (ja) | 2003-07-11 | 2011-12-14 | − ツァチェルニュウク、タティアナ、アー. エゴロワ | 生体化合物の安定同位体標識のための組成物及び方法 |
JP2006053100A (ja) * | 2004-08-13 | 2006-02-23 | Institute Of Physical & Chemical Research | 動物の代謝解析方法、ラベル動物の製造方法、ラベル動物、および、動物のnmr測定方法 |
EP1637163A1 (en) * | 2004-09-21 | 2006-03-22 | Andreas Kluge | Indicator of therapeutic compliance |
BRPI0516803A (pt) * | 2004-11-19 | 2008-09-23 | Martek Biosciences Corp | oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
GB0604647D0 (en) | 2006-03-08 | 2006-04-19 | Shchepinov Mikhail | Stabilized food supplements and their derivatives |
US20080234197A1 (en) * | 2007-03-19 | 2008-09-25 | Undurti N Das | Method(s) of stabilizing and potentiating the actions and administration of brain-derived neurotrophic factor (BDNF) |
CN105330743B (zh) | 2007-08-02 | 2019-05-28 | 吉利德生物制剂公司 | Lox和loxl2抑制剂及其应用 |
US20090069354A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched gemcitabine |
WO2009114814A2 (en) | 2008-03-14 | 2009-09-17 | Retrotope, Inc. | Therapeutic substances that modulate genome methylation |
WO2009114809A1 (en) | 2008-03-14 | 2009-09-17 | Retrotope, Inc. | Therapies for cancer using isotopically substituted lysine |
-
2006
- 2006-03-08 GB GBGB0604647.8A patent/GB0604647D0/en not_active Ceased
-
2007
- 2007-03-08 WO PCT/GB2007/050112 patent/WO2007102030A1/en active Application Filing
- 2007-03-08 EP EP07712990.6A patent/EP1991068B8/en active Active
- 2007-03-08 JP JP2008557833A patent/JP5844955B2/ja active Active
- 2007-03-08 CA CA2931996A patent/CA2931996A1/en not_active Abandoned
- 2007-03-08 EP EP17174428.7A patent/EP3339315B1/en active Active
- 2007-03-08 ES ES07712990.6T patent/ES2639395T3/es active Active
- 2007-03-08 CA CA2645038A patent/CA2645038C/en active Active
- 2007-03-08 US US12/281,957 patent/US8906405B2/en active Active
- 2007-03-08 DK DK07712990.6T patent/DK1991068T3/en active
-
2014
- 2014-11-24 US US14/551,450 patent/US9320289B2/en active Active
-
2015
- 2015-03-09 JP JP2015045737A patent/JP6062470B2/ja active Active
-
2016
- 2016-03-23 US US15/078,853 patent/US9616042B2/en active Active
-
2017
- 2017-03-01 US US15/446,922 patent/US10015979B2/en active Active
-
2018
- 2018-06-22 US US16/016,023 patent/US10918126B2/en active Active
- 2018-12-21 HK HK18116375.1A patent/HK1260326A1/zh unknown
Non-Patent Citations (3)
Title |
---|
JPN6016006031; de Sain-van der Velden,M.G. et al: 'Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results' Kidney Int. Vol.53, No.4, 199804, p.994-1001 * |
JPN6016006034; Mattison,L.K. et al.: 'Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil bre' Clin. Cancer Res. Vol.10, No.8, 20040415, p.2652-8 * |
JPN6016006035; Geboes,K.P. et al.: 'Validation of a new test meal for a protein digestion breath test in humans.' J. Nutr. Vol.134, No.4, 200404, p.806-10 * |
Also Published As
Publication number | Publication date |
---|---|
US20100160248A1 (en) | 2010-06-24 |
EP1991068A1 (en) | 2008-11-19 |
EP1991068B8 (en) | 2018-10-17 |
US20180303145A1 (en) | 2018-10-25 |
EP3339315C0 (en) | 2023-10-18 |
US10918126B2 (en) | 2021-02-16 |
GB0604647D0 (en) | 2006-04-19 |
US20150147457A1 (en) | 2015-05-28 |
US9320289B2 (en) | 2016-04-26 |
CA2931996A1 (en) | 2007-09-13 |
US8906405B2 (en) | 2014-12-09 |
CA2645038C (en) | 2016-08-16 |
ES2639395T3 (es) | 2017-10-26 |
EP3339315B1 (en) | 2023-10-18 |
JP5844955B2 (ja) | 2016-01-20 |
US9616042B2 (en) | 2017-04-11 |
JP6062470B2 (ja) | 2017-01-18 |
JP2009528833A (ja) | 2009-08-13 |
DK1991068T3 (en) | 2017-09-11 |
HK1260326A1 (zh) | 2019-12-20 |
US20160263066A1 (en) | 2016-09-15 |
WO2007102030A1 (en) | 2007-09-13 |
US20170172195A1 (en) | 2017-06-22 |
EP3339315A1 (en) | 2018-06-27 |
CA2645038A1 (en) | 2007-09-13 |
EP1991068B1 (en) | 2017-06-07 |
US10015979B2 (en) | 2018-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6062470B2 (ja) | 同位体修飾化合物およびフードサプリメントとしてのそれらの使用 | |
EP2402453A2 (en) | Method for increasing methionine productivity using a mixture of methyl mercaptan and dimethyl sulfide | |
EP2692719B1 (en) | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof | |
JP2014185163A (ja) | 同位体で置換されたリジンを用いたがん治療 | |
Seki | Biological significance and development of practical synthesis of biotin | |
JP5180421B2 (ja) | クレアチンエステル代替栄養素化合物及び調合物 | |
England et al. | Incorporation of esters into proteins: Improved synthesis of hydroxyacyl tRNAs | |
AU2001290939A1 (en) | Creatine ester pronutrient compounds and formulations | |
US20030212136A1 (en) | Creatine ester pronutrient compounds and formulations | |
US20220055978A1 (en) | Method for producing capped 3-hydroxycarboxylic acids and their salts and esters | |
Brand et al. | Some aspects of intermediary protein metabolism | |
Poluboyarinov et al. | The synthesis and biological activity of 3, 3'-dimethyl-L-selenocystine, a new selenocystine derivative | |
US20230020342A1 (en) | Method for producing polyol-based esters, in particular polyglycerol esters, from hydroxy carboxylic acids | |
CN118063351B (zh) | 使用生物酶绿色合成手性β氨基酸和使用的固定化转氨酶 | |
JP5689892B2 (ja) | 2−アミノ−3−メチル−ヘキサ−5エン酸、及びバシトラシン等のペプチドの生成におけるその使用方法 | |
CN113943333A (zh) | 一种氢化烟酰胺核糖的制备方法及应用 | |
Matsuno | End products of glutamine oxidation in MC-29 virus-induced chicken hepatoma mitochondria | |
CN110699343A (zh) | 一种用于γ-D谷氨酰肽合成的酶及γ-D谷氨酰肽的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160223 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160822 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6062470 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |